Skip to content

Study · Not a test of the peptide alone · 1987

3 results

Tumor-promoting phorbol esters interfere with the vasoactive intestinal peptide receptor/effector system in rat prostatic epithelial cells.

Escudero F, Carmena MJ, Prieto JC

Biochemical and biophysical research communications1 Nov 1987Cited by 6 (Europe PMC)

PMID2825698 (opens in a new tab)DOI10.1016/0006-291x(87)91627-5 (opens in a new tab)PepBankPUB-02825698
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In rat prostatic epithelial cells, pretreatment with a tumour-promoting phorbol ester decreased the potency of VIP in stimulating cyclic AMP accumulation.

    In plain wordsIn rat prostate cells, a phorbol ester made VIP less able to raise cyclic AMP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseVIP potency on cyclic AMP accumulation after phorbol ester pretreatment
    Study

    ratn: not reported in source

    Rat prostatic epithelial cells
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    resulted in a decrease of both the potency of vasoactive intestinal peptide (VIP) upon the stimulation of cyclic AMP accumulation
    1 context sentence
    Summary · context
    Pretreatment of rat prostatic epithelial cells with the tumor-promoting phorbol ester 4 beta-phorbol 12-myristate 13-acetate resulted in a decrease of both the potency of vasoactive intestinal peptide (VIP) upon the stimulation of cyclic AMP accumulation and the affinity of the receptors of this peptide.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In rat prostatic epithelial cells, pretreatment with a tumour-promoting phorbol ester decreased the affinity of the VIP receptors.

    In plain wordsIn rat prostate cells, a phorbol ester made the VIP receptors bind VIP less well.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseVIP receptor affinity after phorbol ester pretreatment
    Study

    ratn: not reported in source

    Rat prostatic epithelial cells
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    resulted in a decrease of both the potency of vasoactive intestinal peptide (VIP) upon the stimulation of cyclic AMP accumulation and the affinity of the receptors of this peptide
    1 context sentence
    Summary · context
    Pretreatment of rat prostatic epithelial cells with the tumor-promoting phorbol ester 4 beta-phorbol 12-myristate 13-acetate resulted in a decrease of both the potency of vasoactive intestinal peptide (VIP) upon the stimulation of cyclic AMP accumulation and the affinity of the receptors of this peptide.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In rat prostatic epithelial cells, the dose-dependent effects of the phorbol ester on the VIP response could be reproduced by other stimulators of protein kinase C.

    In plain wordsIn rat prostate cells, other protein kinase C stimulators also lowered the cell response to VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseEffect of other protein kinase C stimulators on VIP response
    Study

    ratn: not reported in source

    Rat prostatic epithelial cells
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    These effects were dose-dependent and could be reproduced by other stimulators of protein kinase C (PKC).
    1 context sentence
    Summary · context
    Pretreatment of rat prostatic epithelial cells with the tumor-promoting phorbol ester 4 beta-phorbol 12-myristate 13-acetate resulted in a decrease of both the potency of vasoactive intestinal peptide (VIP) upon the stimulation of cyclic AMP accumulation and the affinity of the receptors of this peptide.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.